Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-474 in healthy volunteers and patients with AD or HS
NCT04772885Phase 1Completed
- Sponsor
- Kymera Therapeutics
- Start
- Feb 2021
- Primary completion
- Oct 2022
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAR444656 in atopic dermatitis (AD) and hidradenitis suppurativa (HS) (5 arms), sponsored by Kymera Therapeutics. Primary endpoints: Incidence and severity of treatment emergent Adverse Events up to 28 days and Incidence and frequency of use of concomitant medication up to 28 days. Started Feb 2021; status: completed.
02
Drugs
SAR444656
03
Conditions
atopic dermatitis (AD)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04772885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772885.